Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free SBTX Stock Alerts

Silverback Therapeutics (SBTX) Competitors

Silverback Therapeutics logo
$7.94 -0.29 (-3.52%)
As of 05/22/2026
Compare

SBTX vs. AVTE, LWAC, ELYM, NLTX, and CNTN

Should you buy Silverback Therapeutics stock or one of its competitors? MarketBeat compares Silverback Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Silverback Therapeutics include Aerovate Therapeutics (AVTE), LightWave Acquisition (LWAC), Eliem Therapeutics (ELYM), Neoleukin Therapeutics (NLTX), and Hillstream Biopharma (CNTN).

How does Silverback Therapeutics compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

74.9% of Silverback Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Silverback Therapeutics had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Silverback Therapeutics and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.00 equaled Silverback Therapeutics'average media sentiment score.

Company Overall Sentiment
Aerovate Therapeutics Neutral
Silverback Therapeutics Neutral

Silverback Therapeutics' return on equity of -29.62% beat Aerovate Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aerovate TherapeuticsN/A -90.19% -77.47%
Silverback Therapeutics N/A -29.62%-28.20%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A

Summary

Silverback Therapeutics beats Aerovate Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Silverback Therapeutics compare to LightWave Acquisition?

Silverback Therapeutics (NASDAQ:SBTX) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

LightWave Acquisition's return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silverback TherapeuticsN/A -29.62% -28.20%
LightWave Acquisition N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A
LightWave AcquisitionN/AN/AN/AN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
LightWave Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Silverback Therapeutics had 1 more articles in the media than LightWave Acquisition. MarketBeat recorded 1 mentions for Silverback Therapeutics and 0 mentions for LightWave Acquisition. Silverback Therapeutics' average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score.

Company Overall Sentiment
Silverback Therapeutics Neutral
LightWave Acquisition Neutral

74.9% of Silverback Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Silverback Therapeutics and LightWave Acquisition tied by winning 3 of the 6 factors compared between the two stocks.

How does Silverback Therapeutics compare to Eliem Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Silverback Therapeutics' return on equity of -29.62% beat Eliem Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silverback TherapeuticsN/A -29.62% -28.20%
Eliem Therapeutics N/A -47.03%-45.97%

Eliem Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A
Eliem TherapeuticsN/AN/A-$35.12M-$0.53N/A

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Silverback Therapeutics and Silverback Therapeutics both had 1 articles in the media. Eliem Therapeutics' average media sentiment score of 0.88 beat Silverback Therapeutics' score of 0.00 indicating that Eliem Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silverback Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Eliem Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Eliem Therapeutics has a beta of -0.39, meaning that its share price is 139% less volatile than the broader market.

Summary

Silverback Therapeutics beats Eliem Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Silverback Therapeutics compare to Neoleukin Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11N/A

Silverback Therapeutics' return on equity of -29.62% beat Neoleukin Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silverback TherapeuticsN/A -29.62% -28.20%
Neoleukin Therapeutics N/A -37.22%-30.91%

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

In the previous week, Silverback Therapeutics had 1 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 1 mentions for Silverback Therapeutics and 0 mentions for Neoleukin Therapeutics. Silverback Therapeutics' average media sentiment score of 0.00 equaled Neoleukin Therapeutics'average media sentiment score.

Company Overall Sentiment
Silverback Therapeutics Neutral
Neoleukin Therapeutics Neutral

Summary

Silverback Therapeutics beats Neoleukin Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Silverback Therapeutics compare to Hillstream Biopharma?

Silverback Therapeutics (NASDAQ:SBTX) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical preparations industry companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, meaning that its stock price is 44% more volatile than the broader market.

Silverback Therapeutics' return on equity of -29.62% beat Hillstream Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Silverback TherapeuticsN/A -29.62% -28.20%
Hillstream Biopharma N/A -31.50%-24.72%

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/A-$89.48M-$2.42N/A
Hillstream BiopharmaN/AN/A-$35.92M-$1.15N/A

In the previous week, Silverback Therapeutics and Silverback Therapeutics both had 1 articles in the media. Silverback Therapeutics' average media sentiment score of 0.00 beat Hillstream Biopharma's score of -0.36 indicating that Silverback Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silverback Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hillstream Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silverback Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Hillstream Biopharma
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

74.9% of Silverback Therapeutics shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 34.4% of Silverback Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Hillstream Biopharma beats Silverback Therapeutics on 6 of the 10 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SBTX vs. The Competition

Export
MetricSilverback TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$286.30M$927.43M$6.46B$12.34B
Dividend YieldN/A4.84%2.76%5.28%
P/E Ratio-3.281.4620.9925.66
Price / SalesN/A119.63560.3086.31
Price / CashN/A20.0743.4956.67
Price / Book1.077.5910.417.14
Net Income-$89.48M-$3.64M$3.57B$335.98M
7 Day Performance8.77%3.01%6.41%4.15%
1 Month Performance-4.22%76.62%3.55%2.54%
1 Year Performance-47.00%126.61%34.12%35.06%

Silverback Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SBTX
Silverback Therapeutics
N/A$7.94
-3.5%		N/A-47.0%$286.30MN/AN/A83
AVTE
Aerovate Therapeutics
N/A$21.88
-0.6%		N/A+215.9%$634.19MN/AN/A20
LWAC
LightWave Acquisition
N/A$10.19
-0.1%		N/AN/A$306.77MN/AN/AN/A
ELYM
Eliem Therapeutics
N/A$9.65
-2.3%		N/A+832.2%$287.11MN/AN/A9
NLTX
Neoleukin Therapeutics
N/A$26.88
-3.9%		N/A+60.4%$252.62MN/AN/A90

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel